Targets › HBV
4 programs from 3 companies in 8 trials: 5 Phase 2, 3 Phase 1; Infectious disease, Genitourinary; next expected readout Dec 2026.
Open in Phaseline: the race on HBV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Maryland, Baltimore | Imdusiran (AB-729) HBsAg antisense oligonucleotide | HBV | Phase 2 | Chronic Hepatitis B | Dec 2026 |
| GSK | Bepirovirsen Antisense oligonucleotide targeting hepatitis B virus RNA | HBV | Phase 2 | Hepatitis B; Chronic Hepatitis B Virus Infection | Apr 2027 |
| GSK | Daplusiran/Tomligisiran RNAi therapeutic targeting hepatitis B virus and host factors | HBV | Phase 2 | Chronic Hepatitis B Virus Infection | May 2027 |
| Michael Hoelscher | TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac) Heterologous protein prime/MVA boost therapeutic hepatitis B vaccine | HBV | Phase 1 | Chronic Hepatitis B | Dec 2026 |
Hepatitis B (3) Chronic Hepatitis B (3) Chronic Hepatitis B Virus Infection (2)
other (3), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.